|
|
Volumn 8, Issue 2, 2009, Pages 98-
|
|
Trial watch: Phase III promise for oral multiple sclerosis therapy.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG DERIVATIVE;
FINGOLIMOD;
IMMUNOSUPPRESSIVE AGENT;
PROPANEDIOL DERIVATIVE;
SPHINGOSINE;
DOUBLE BLIND PROCEDURE;
HUMAN;
MULTIPLE SCLEROSIS;
NOTE;
ORAL DRUG ADMINISTRATION;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
ADMINISTRATION, ORAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
DOUBLE-BLIND METHOD;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MULTIPLE SCLEROSIS;
PROPYLENE GLYCOLS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SPHINGOSINE;
MLCS;
MLOWN;
|
|
EID: 59849083897
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2821 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|